. . . "0"^^ . "The project was fulfilled in an excellent way and yielded preparation and characterization of new synthetic inhibitors of cyclin-dependent kinases that have a potential for development into anticancer drugs. The obtained results were published in a series of high quality papers and received attention of the interbnational research community."@en . "Synthetic inhibitors of cyclin-dependent kinases (CDK) have been developed as drugs for various diseases including cancers. The team of applicant has long-term experiences with the development of CDK inhibitors, including synthesis, biochemical characterization and evaluation of in vitro and in vivo effects. The objective of this project application is to study molecular mechanisms of action of our newly prepared potent CDK inhibitors in specific cancer cell lines (neuroblastoma, breast carcinoma, hepatocarcinoma, multiple myeloma) that that were recently found to be dependent on activity of certain CDKs and where inactivation of these CDKs in a combination with specific genetic background causes strong synthetic lethality. In a parallel approach, we will study relationships between selectivity of CDK inhibitors and their cytotoxicity. The project should help to select the right CDK inhibitor for particular cancer types and to increase therapeutic benefit to patients."@en . . "2012-01-01+01:00"^^ . . "GAP305/12/0783" . . . . "http://www.isvav.cz/projectDetail.do?rowId=GAP305/12/0783"^^ . . "Syntetick\u00E9 inhibitory cyklin-dependentn\u00EDch kinas (CDK) jsou v sou\u010Dasnosti vyv\u00EDjeny se z\u00E1m\u011Brem vyu\u017E\u00EDt je p\u0159i l\u00E9\u010Db\u011B n\u011Bkter\u00FDch typ\u016F onemocn\u011Bn\u00ED v\u010Detn\u011B rakoviny. Pracovi\u0161t\u011B navrhovatele a spolunavrhovatele m\u00E1 dlouhodob\u00E9 zku\u0161enosti s v\u00FDvojem inhibitor\u016F CDK od synt\u00E9zy, p\u0159es biochemickou charakterizaci a\u017E k posuzov\u00E1n\u00ED \u00FA\u010Dink\u016F in vitro a in vivo. Podstatou tohoto grantov\u00E9ho n\u00E1vrhu je studium molekul\u00E1rn\u00EDho mechanismu p\u016Fsoben\u00ED n\u00E1mi ned\u00E1vno p\u0159ipraven\u00FDch nov\u00FDch inhibitor\u016F CDK v konkr\u00E9tn\u00EDch n\u00E1dorov\u00FDch bun\u011B\u010Dn\u00FDch lini\u00EDch (neuroblastom, prsn\u00ED karcinom, hepatocelul\u00E1rn\u00ED karcinom, mnoho\u010Detn\u00FD myelom), v nich\u017E lze na z\u00E1klad\u011B specifick\u00E9ho genetick\u00E9ho pozad\u00ED o\u010Dek\u00E1vat v\u00FDrazn\u00FD \u00FA\u010Dinek (syntetickou letalitu) v kombinaci s ur\u010Dit\u00FDmi dal\u0161\u00EDmi chemoterapeutiky. V\u00FDsledky projektu mohou pomoci vybrat vhodn\u00FD CDK inhibitor pro terapii konkr\u00E9tn\u00EDch typ\u016F n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED." . . "Projekt byl spln\u011Bn skv\u011Bl\u00FDm zp\u016Fsobem a umo\u017Enil v\u00FDvoj a detailn\u00ED charakterizaci nov\u00FDch vysoce \u00FA\u010Dinn\u00FDch inhibitor\u016F cyklin-dependentn\u00EDch kinas s potenci\u00E1lem vyu\u017Eit\u00ED p\u0159i l\u00E9\u010Db\u011B rakoviny. Dosa\u017Een\u00E9 v\u00FDsledky otev\u00EDraj\u00ED cestu k v\u00FDvoji nov\u00FDch l\u00E9\u010Div a byly kvalitn\u011B publikov\u00E1ny v s\u00E9rii prac\u00ED, je\u017E vzbudily mezin\u00E1rodn\u00ED ohlas."@cs . . . . "2015-05-22+02:00"^^ . "2014-12-31+01:00"^^ . "12"^^ . . "Vliv genetick\u00E9ho pozad\u00ED na citlivost n\u00E1dorov\u00FDch bun\u011B\u010Dn\u00FDch lini\u00ED k inhibitor\u016Fm cyklin-dependentn\u00EDch kinas" . "12"^^ . . "1"^^ . . "Evaluation of cyclin-dependent kinase inhibitors in cancer cell lines with specific genetic alterations"@en . "cyklin-dependent kinase inhibitor roscovitine synthetic lethality cancer"@en . . . "1"^^ . "2014-06-03+02:00"^^ . .